Incidence and risk factors of cetuximab-induced hypersensitivity infusion reactions (HIRs).

e19531 Background: The reported national incidence of grade 3/4 hypersensitivity infusion reactions (HIRs) with cetuximab is approximately 3%. The purpose of this study is to estimate the incidence...